Free Trial

Aclaris Therapeutics (ACRS) Competitors

Aclaris Therapeutics logo
$1.46 +0.02 (+1.39%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$1.50 +0.04 (+2.74%)
As of 08:56 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACRS vs. STOK, SANA, MRVI, URGN, AUTL, CDXC, CDTX, ABUS, EOLS, and UPB

Should you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Stoke Therapeutics (STOK), Sana Biotechnology (SANA), Maravai LifeSciences (MRVI), Urogen Pharma (URGN), Autolus Therapeutics (AUTL), ChromaDex (CDXC), Cidara Therapeutics (CDTX), Arbutus Biopharma (ABUS), Evolus (EOLS), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry.

Aclaris Therapeutics vs. Its Competitors

Aclaris Therapeutics (NASDAQ:ACRS) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Aclaris Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Aclaris Therapeutics presently has a consensus price target of $9.71, suggesting a potential upside of 565.36%. Stoke Therapeutics has a consensus price target of $23.20, suggesting a potential upside of 98.46%. Given Aclaris Therapeutics' higher probable upside, research analysts clearly believe Aclaris Therapeutics is more favorable than Stoke Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aclaris Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11
Stoke Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.29

98.3% of Aclaris Therapeutics shares are owned by institutional investors. 6.4% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Stoke Therapeutics had 9 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 12 mentions for Stoke Therapeutics and 3 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.70 beat Stoke Therapeutics' score of 0.18 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aclaris Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Stoke Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Stoke Therapeutics has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclaris Therapeutics$18.72M8.44-$132.07M-$1.39-1.05
Stoke Therapeutics$36.56M17.46-$88.98M$0.7914.80

Stoke Therapeutics has a net margin of 26.33% compared to Aclaris Therapeutics' net margin of -732.42%. Stoke Therapeutics' return on equity of 19.08% beat Aclaris Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aclaris Therapeutics-732.42% -30.73% -22.74%
Stoke Therapeutics 26.33%19.08%15.72%

Summary

Stoke Therapeutics beats Aclaris Therapeutics on 13 of the 17 factors compared between the two stocks.

Get Aclaris Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACRS vs. The Competition

MetricAclaris TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$155.93M$2.41B$5.51B$9.02B
Dividend YieldN/A1.78%5.24%4.05%
P/E Ratio-1.058.7527.2120.09
Price / Sales8.44476.02370.4792.99
Price / CashN/A21.7726.2128.59
Price / Book1.014.497.945.55
Net Income-$132.07M$31.26M$3.17B$248.49M
7 Day Performance3.55%1.27%1.79%4.87%
1 Month Performance-4.58%2.46%1.27%6.63%
1 Year Performance14.96%-0.29%33.56%20.38%

Aclaris Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACRS
Aclaris Therapeutics
2.6215 of 5 stars
$1.46
+1.4%
$9.71
+565.4%
+21.7%$155.93M$18.72M-1.05100Gap Up
STOK
Stoke Therapeutics
3.9941 of 5 stars
$11.35
-2.4%
$23.20
+104.4%
-10.9%$634.96M$36.56M14.37100
SANA
Sana Biotechnology
2.5623 of 5 stars
$2.73
-2.8%
$8.60
+215.0%
-39.1%$633.59MN/A-3.10380
MRVI
Maravai LifeSciences
3.8635 of 5 stars
$2.41
-2.4%
$6.64
+175.5%
-62.8%$629.01M$259.18M-2.11610
URGN
Urogen Pharma
4.5354 of 5 stars
$13.70
+1.6%
$32.86
+139.8%
-15.1%$621.99M$90.40M-4.31200Analyst Forecast
AUTL
Autolus Therapeutics
2.1233 of 5 stars
$2.28
-1.3%
$9.32
+308.8%
-34.5%$614.79M$10.12M-2.59330
CDXC
ChromaDex
3.1982 of 5 stars
N/A$9.03
+∞
N/A$611.50M$99.60M787.29120
CDTX
Cidara Therapeutics
4.2156 of 5 stars
$48.71
-1.5%
$57.14
+17.3%
+300.8%$603.74M$1.27M-1.6590High Trading Volume
ABUS
Arbutus Biopharma
1.4488 of 5 stars
$3.09
-1.3%
$5.50
+78.0%
+0.6%$599.48M$6.17M-7.5490
EOLS
Evolus
3.6694 of 5 stars
$9.21
+0.8%
$23.75
+157.9%
-16.4%$589.31M$266.27M-10.35170Positive News
UPB
Upstream Bio
N/A$10.98
+0.5%
$56.50
+414.6%
N/A$587.97M$2.37M0.0038

Related Companies and Tools


This page (NASDAQ:ACRS) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners